**Identifying and appraising outcome measures for severe asthma: a systematic review**

**Authors:** Anna Rattu, Ekaterina Khaleva, Chris Brightling, Sven-Erik Dahlén, Apostolos Bossios, Louise Fleming, Kian Fan Chung, Erik Melén, Ratko Djukanovic, Rekha Chaudhuri, Andrew Exley, Gerard H. Koppelman, Arnaud Bourdin, Franca Rusconi, Celeste Porsbjerg, Courtney Coleman, Clare Williams, Hanna Nielsen, Elizabeth Davin, Phil Taverner, Sofia Romagosa Vilarnau, Graham Roberts on behalf of the 3TR consortium Respiratory Work Package.

**Affiliations:**

Anna Rattu, Clinical and Experimental Sciences and Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, UK. ORCID: 0000-0002-7497-9552.

Ekaterina Khaleva, Clinical and Experimental Sciences and Human Development and Health, Faculty of Medicine,

University of Southampton, Southampton, UK. ORCID: 0000-0002-2220-7745.

Chris Brightling, Institute for Lung Health, Leicester NIHR BRC, University of Leicester, UK. ORCID: 0000-0002-9345-4903.

Sven-Erik Dahlén, Department of Respiratory Medicine and Allergy, Karolinska University Hospital, Huddinge and Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden. ORCID: 0000-0002-4993-4002.

Apostolos Bossios, Department of Respiratory Medicine and Allergy, Karolinska University Hospital,

Huddinge and Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden. ORCID:

0000-0002-0494-2690.

Louise Fleming, National Heart and Lung Institute, Imperial College, London, UK. ORCID: 0000-0002-7268-7433.

Kian Fan Chung, National Heart & Lung Institute, Imperial College London, London. UK. ORCID: 0000-0001-

7101-1426.

Erik Melén, Department of Clinical Science and Education Södersjukhuset, Karolinska Institutet, Stockholm,

Sweden. ORCID: 0000-0002-8248-0663.

Ratko Djukanovic, NIHR Southampton Biomedical Research Centre, University Hospital Southampton,

Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Sir Henry Wellcome

Laboratories, Southampton, UK. ORCID: 0000-0001-6039-5612.

Rekha Chaudhuri, Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, UK. ORCID: 0000-0001-8007-949X.

Andrew Exley, Co-Director, Adept Biologica Consulting Limited, London, UK. ORCID: 0000-0002-2628-6129.

Gerard H. Koppelman, University of Groningen, University Medical Center Groningen, Beatrix Children’s Hospital, Department of Paediatric Pulmonology and Paediatric Allergology, Groningen, the Netherlands; University of Groningen, University Medical Center Groningen, Groningen Research Institute for Asthma and COPD (GRIAC), Groningen, the Netherlands. ORCID 0000-0001-8567-3252.

Arnaud Bourdin, PhyMedExp, University of Montpellier, Montpellier, France.

Franca Rusconi, Department of Mother and Child Health, Azienda USL Toscana Nord Ovest, Pisa, Italy.

ORCID: 0000-0002-9544-6472.

Celeste Porsbjerg, Department of Respiratory Medicine, Respiratory Research Unit, Bispebjerg Hospital,

Copenhagen, Denmark. ORCID: 0000-0003-4825-9436.

Courtney Coleman, European Lung Foundation (ELF), Sheffield, UK. ORCID: 0000-0001-7687-1273.

Clare Williams, European Lung Foundation (ELF), Sheffield, UK. ORCID 0000-0001-9446-0339.

Hanna Nielsen, Faculty of Medicine, Karolinska Institutet Stockholm, Sweden; 3TR Patient Working Group.

Elizabeth Davin, 3TR Patient Working Group.

Phil Taverner, 3TR Patient Working Group.

Sofia Romagosa Vilarnau, European Federation of Allergy and Airways Diseases Patients’ Associations (EFA),

Brussels, Belgium.

Graham Roberts, Clinical and Experimental Sciences and Human Development, University of Southampton, University Road, Highfield, Southampton, UK. NIHR Southampton Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK. David Hide Asthma and Allergy Centre, St Mary’s Hospital, Isle of Wight, UK.

**Correspondence address:** Professor Graham Roberts, Paediatric Allergy and Respiratory Medicine, University Child Health (MP803), University Hospital, Southampton NHS Foundation Trust, Tremona Road, Southampton SO16 6YD, UK. Tel.: +44 (0) 2380796160, E-mail: [g.c.roberts@soton.ac.uk](mailto:g.c.roberts@soton.ac.uk).

**ABSTRACT**

**Background:** Valid outcome measures are imperative to evaluate treatment response, yet the suitability of existing endpoints for severe asthma is unclear. This review aimed to identify outcome measures for severe asthma and appraise the quality of their measurement properties.

**Methods:** A literature search was performed to identify ‘candidate’ outcome measures published between 2018 – 2020 (PROSPERO, CRD42020204437). A modified Delphi exercise was conducted to select ‘key’ outcome measures within healthcare professional, patient, pharmaceutical, and regulatory stakeholder groups. Initial validation studies for ‘key’ measures were rated against modified quality criteria from COnsensus-based Standards for the selection of health Measurement Instruments (COSMIN). The evidence was discussed at multi-stakeholder meetings to ratify ‘priority’ outcome measures. Subsequently, four bibliographic databases were searched from inception to identify development and validation studies for these endpoints. Two reviewers screened records, extracted data, assessed their methodological quality, and graded the evidence according to COSMIN.

**Results:** 96 outcome measures were identified as ‘candidates’, 55 as ‘key’, and 24 as ‘priority’ for severe asthma; including clinical, healthcare utilisation, quality of life, asthma control, and composite. 32 studies reported measurement properties of 17 ‘priority’ endpoints from the latter three domains. Only SAQ and C-ACT were developed with input from severe asthma patients. The certainty of evidence was ‘low’ to ‘very low’ for most ‘priority’ endpoints across all measurement properties, and none fulfilled all quality standards.

**Conclusion:** Only two outcome measures had robust developmental data for severe asthma. This review informed development of core outcome measures sets for severe asthma.

**Keywords:** COSMIN, measurement properties, outcome measures,validity,severe asthma, systematic review

**Take home message:** This study identified and appraised the validity of selected outcome measures for severe asthma with input from key stakeholders. Only the Severe Asthma Questionnaire and Childhood Asthma Control Test had robust developmental data for severe asthma.

**Abbreviations:** ATS / ERS (American Thoracic Society / European Respiratory Society), AQLQ (Asthma Quality Of Life Questionnaire), AQLQ-S (Asthma Quality Of Life Questionnaire Standardised), Mini-AQLQ (Mini Asthma Quality Of Life Questionnaire), ACT (Asthma Control Test), ACQ (Asthma Control Questionnaire), ACCI (Asthma Control and Communication Instrument), C-ACT (Childhood Asthma Control Test), CASI (Composite Asthma Severity Index), COSMIN (COnsensus-based Standards for the selection of health Measurement Instruments), FDA (Food and Drug Administration), FEV (forced expiratory volume), FeNO (fractional exhaled nitric oxide), GRADE (Grading of Recommendations Assessment, Development and Evaluation), HRU (Healthcare resource utilisation), MCID (Minimal Clinical Important Difference), Mini-PAQLQ (Mini Paediatric Asthma Quality Of Life Questionnaire), mOCS (maintenance oral corticosteroids), OCS (Oral corticosteroids), PAQLQ (Paediatric Asthma Quality Of Life Questionnaire), PAQLQ-S (Paediatric Asthma Quality Of Life Questionnaire Standardised), PROM (Patient-reported Outcome Measures), QoL (Quality of Life), RoB (Risk of Bias), SAQ (Severe Asthma Questionnaire), St George’s Respiratory Questionnaire (SGRQ).

# BACKGROUND

Asthma is the most prevalent chronic respiratory condition affecting an estimated 339 million people worldwide1-3. Approximately 5-10% of these patients have severe asthma2,4. The American Thoracic Society / European Respiratory Society (ATS/ERS), define severe asthma as requiring treatment with high-dose inhaled corticosteroids plus additional controller medication(s) or oral corticosteroids (OCS) to maintain disease control, or which remains sub-optimally controlled despite adherence once differential diagnoses have been addressed and any co-morbidities treated2. The impaired quality of life (QoL), adverse effects of long term OCS use, and disproportionately high healthcare cost are causes of concern in this group of patients5-10.

A more nuanced understanding of the pathophysiological mechanisms underlying severe asthma has facilitated the emergence of new-generation treatments, including ‘biologics’, which can reduce exacerbation rates11, OCS use12, and improve lung function13. In studies investigating these interventions the selection of efficacy endpoints is influenced by multiple aspects of trial design and analysis. However, it is imperative that the outcome measures have robust measurement properties to ensure good quality and appropriate interpretation of results. The selection of outcome measures should be grounded in whether they are valid, reliable, and responsive and sensitive to changes when evaluating differences in the treatment groups14.

The National Institutes of Health (NIH) recommendations15-20 for outcome measurement instruments for asthma are the *status quo* for clinical practice and research, yet there is no consensus on which outcome measures are important to patients with severe asthma and have robust psychometric properties in this population. Further, guidelines recommend the implementation of patient-reported outcome measures (PROMs) capturing domains such as QoL and asthma control to evaluate treatment response, but do not propose specific instruments21. On the other hand, outcomes that patients consider a treatment priority, such as QoL8,22, are not consistently reflected in physicians’ approach to evaluating treatment response23. It is particularly important to use patient-centred outcome measures in effectiveness studies of biologics to justify the high economic24 and individual-level treatment burden6,8,25. A comprehensive view of the validity of outcome measures for severe asthma would also enable the selection of the most appropriate instruments for better disease management by patients and healthcare professionals in practice.

This systematic review aimed to (i) identify patient-centred outcome measures considered to be a ‘priority’ for severe asthma by relevant stakeholders (patient representatives, which included patients, parents/carers, and patient advocacy organisations; healthcare professionals, pharmaceutical, and regulatory representatives) and, (ii) critically appraise, compare, and qualitatively summarize the quality of studies reporting the development and measurement properties of each ‘priority’ outcome measure using the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) guidelines26,27.

# METHODS

This systematic review is registered with the International Prospective Register of Systematic Reviews (PROSPERO registration: CRD42020204437). The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist has been used to guide the reporting of this systematic review28 **(Appendix D.1)**. The methods are described in **Figure 1** and full details are reported in the online supplement **(Appendix A and B).**

## Steps 1 – 3: Identifying ‘priority’ outcome measures for severe asthma

In Step 1, a literature search was performed to identify ‘candidate’ outcome measures (patient-reported, clinical, composite, and imaging) published in four bibliographic databases between May 7, 2018 – May 7, 2020. Subsequently, a modified Delphi exercise was conducted within four stakeholder groups recruited from across Europe (Step 2). This involved two consecutive rounds of surveys wherein stakeholders ranked the importance of ‘candidate’ outcome measures on a 9-point Likert scale (based on Grading of Recommendations Assessment, Development and Evaluation (GRADE)29). ‘Candidate’ outcome measures which ≥50% participants in each stakeholder group rated as critical (7-9 on 9-point Likert scale) were ratified as ‘key’ outcome measures; measures for which consensus was not achieved were discussed at a multi-stakeholder web-conference to obtain agreement on whether they should be classified as ‘key’. Emphasis was placed on collating views about ‘candidate’ outcome measures ranked as ‘critical’ and ‘important’ by patient representatives in the round two survey.

Step 3 involved a literature search to identify initial validation studies for selected ‘key’ outcome measures, followed by appraisal of the quality of measurement property results against modified COSMIN quality criteria. The evidence was discussed at two multi-stakeholder meetings together with supporting patient-voice evidence30, followed by online voting to select ‘priority’ outcome measures for adult and paediatric severe asthma. For this voting process data were grouped by patient representatives, and ‘academic’ representatives inclusive of healthcare professionals, pharmaceutical, and regulatory representatives. Outcome measures which ≥33% participants in at least one of two stakeholder groups voted as a ‘priority’ were included.

## Step 4: Development and measurement properties of ‘priority’ outcome measures

### Search strategy

A search strategy was developed on EMBASE (OVID) and subsequently adapted for the following databases: MEDLINE (OVID), CINAHL (EBSCOhost, Cumulative Index to Nursing and Allied Health Literature), and ISI Web of Science (Thomson Web of Knowledge) **(Appendix B.2)**. Databases were searched from the inception to 20 July 2020. The citation lists of identified studies and reference lists of systematic reviews were searched for additional articles.

### Eligibility criteria

The inclusion criteria to identify eligible studies were as follows:

Population: adults (≥ 18 years) and/or children and adolescents (6-17 years) with a diagnosis of asthma. We collated data for all severities of asthma and accounted for the differing relevance for severe asthma in the modified GRADE assessment.

Intervention: any asthma therapy or no intervention.

Comparator: any comparator group including placebo or no comparator.

Study outcomes: outcome measures considered a ‘priority’ by key stakeholders (**Appendix A.4**). For patient-reported and composite outcome measures, studies were also eligible if they validated the ‘priority’ outcome measure with minor modifications according to cultural setting e.g. changing the list of activities to includes items that are more suited to tropical/cold climate.

Study designs: studies aiming to develop (‘development’ or ‘inauguration’ article), investigate the content validity (extent to which the outcome measure assesses the concept of interest) and/or one or more measurement properties of a ‘priority’ outcome measure (including studies with age and sociodemographic subgroups, and different modes of administration).

The exclusion criteria were as follows: systematic reviews and meta-analyses, narrative reviews, discussion papers, commentaries, non-research letters and editorials, abstracts only (e.g. conference paper), animal studies, non-asthma studies e.g. viral bronchiolitis, viral associated wheeze. Studies which reported on linguistic validity, translated, or modified versions of ‘priority’ patient-reported and composite outcome measures, or used ‘priority’ measures as outcome measurement instruments, such as clinical trials, were also excluded. Studies reporting correlations between a ‘priority’ clinical outcome measure and guidelines as ‘gold standard’ were excluded as they are susceptible to publication bias.

### Study selection and data extraction

References were pooled and de-duplicated in Endnote version X9 (Thomson Reuters, Philadelphia, PA), and subsequently uploaded to Rayyan31 (rayyan.qcri.org). Study titles, abstracts, and full-text articles were screened independently by two reviewers (AR, EK) according to the predefined selection criteria. Data extraction from included articles was performed into a pilot-tested form based on the COSMIN guidelines26,27 by one reviewer (AR), and cross-checked by the second reviewer (EK). Any disagreements were resolved through discussion, and, if necessary, involvement of the third reviewer (GR).

### Quality appraisal strategy

The methodological quality and certainty of evidence was evaluated in a three-step process by two independent reviewers (AR, EK). Any discrepancies were resolved through discussion, or arbitration by the third reviewer (GR). First, the Risk of Bias (RoB) of developmental, content validation, and studies reporting other measurement properties was assessed using the COSMIN checklist for PROMs26,32. For non-patient reported outcomes (including composites with clinician-performed components), a separate checklist33 was used. The definitions of measurement properties are provided in Table S3. Second, results of the measurement properties from each study were rated against quality criteria **(**Table S2**)** and qualitatively pooled to generate an overall rating of sufficient (+), insufficient (-), or indeterminate (?). Third, the certainty of evidence was determined using a modified GRADE approach26,32,34. The results were summarized using narrative synthesis.

# RESULTS

## Steps 1-3: Identifying ‘priority’ outcome measures for severe asthma

The detailed results for identifying ‘priority’ outcome measures for severe asthma can be found in **Appendix C**. Briefly, a total of 96 ‘candidate’ outcome measures were retrieved from the literature search. 55 ‘key’ outcome measures were selected following the modified Delphi exercise. Validation data were available for 32 ‘key’ patient-reported and composite outcome measures, and one healthcare resource utilisation (HRU) measure, while no data were identified for clinical outcome measures. The ‘priority’ outcome measures selected following the multi-stakeholder meetings and online voting are presented in **Figure 2**.

## Step 4: Appraisal of development and measurement properties of ‘priority’ outcome measures

### Study characteristics

A total of 32 studies were included; 16 met the inclusion criteria for the adult population, 12 studies for the paediatric population, while 4 were eligible for both populations (**Figure 3**). The characteristics of included studies are presented in Tables S35 and S36 for adult and paediatric populations respectively**.** 12 and seven articles described the development and/or measurement properties of QoL measures for adults35-46, and children and adolescents47-53, respectively. Only one content validation study was identified54. Six articles reported the development and/or measurement properties of asthma control instruments for adults55-60, while eight articles were included for the paediatric population55,56,58,60-64. One study validated the Asthma Control and Communication Instrument (ACCI), a composite tool prioritised for adults65, and one reported the Composite Asthma Severity Index (CASI), a tool for patients older than 6 years66. Of the included studies, ten involved participants with severe asthma; but in most cases the percentage of this population was <50%, and differing definitions of asthma were used (including guidelines, physician diagnosis, and self-report).

### Risk of bias and quality of evidence for ‘priority’ outcome measures

The developmental process for the ‘priority’ outcome measures can be found in Table S32-S34. The characteristics of the ‘priority’ QoL, asthma control, and composite outcome measures are presented in **Table 1**. An overview of the rating of measurement property results against COSMIN quality criteria, and the quality of evidence per ‘priority’ outcome measure for adult and paediatric severe asthma is presented in **Table 2**. Structural validity (for asthma control measures based on a reflective model) and measurement error were not assessed in any of the identified studies. The most common reason for downgrading was indirectness, as <50% of participants in multiple studies had severe asthma.

According to the COSMIN RoB checklist, the assessments for studies ranged from ‘inadequate’ to ‘very good’(Tables S37 and S38) . For ‘doubtful’ or ‘inadequate’ ratings, frequent methodological limitations included lack of description of subgroup characteristics for test-retest reliability; small sample size; inappropriate statistical methods for evaluating responsiveness (or reporting of responsiveness index only), and lack of information on unidimensionality when assessing internal consistency.

#### ‘Priority’ quality of life outcome measures for adult severe asthma

Content validity was rated most favourably for the Severe Asthma Questionnaire (SAQ) with sufficient ‘moderate’ quality evidence across all domains. The SAQ was the only ‘priority’ measure developed with input from adults with severe asthma. The Asthma Quality of Life Questionnaire (AQLQ) and its *ad hoc* standardised and mini versions had variable ratings with ‘low’ to ‘very low’ quality evidence.

For internal consistency there was sufficient ‘very low’ to ‘moderate’ quality evidence for the AQLQ, the Asthma Quality of Life Questionnaire Standardised (AQLQ-S) and Mini-AQLQ. Likewise, all measures had good to excellent test-retest reliability, but the quality of evidence was variable, with only the SAQ scored as ‘moderate’ quality evidence. The Mini-AQLQ showed strong correlation with AQLQ scores, indicating sufficient criterion validity. Only the Mini-AQLQ and SAQ had sufficient evidence for construct validity – scores on both instruments had strong correlations with comparator QoL measures, and weak correlations with FEV1% predicted. The AQLQ and AQLQ-S had sufficient, but ‘low’ and ‘very low’ quality evidence for responsiveness to change; the change scores for patients who were unstable between study visits exceeded the Minimal Clinical Important Difference (MCID).

#### ‘Priority’ asthma control outcome measures for adult severe asthma

The Asthma Control Test (ACT), Asthma Control Questionnaire 5 (ACQ-5), and ACQ-6 had insufficient to inconsistent evidence for content validity. The quality of evidence was ‘very low’ primarily because no patients were involved in the developmental process. However, all the questionnaires had good to excellent internal consistency and test-retest reliability to support the sufficient ratings. The shortened ACQ-6 and ACQ-5 showed strong correlations with the original ACQ-760, illustrating sufficient criterion validity. In contrast, there was insufficient ‘low’ to ‘very low’ quality evidence for construct validity and responsiveness to change for all asthma control instruments. There were studies reporting moderate correlations between scores on ‘priority’ instruments and comparators such as physician assessed asthma control and QoL, and weak correlations with FEV1. Similarly, some studies reported that patients with unstable asthma had meaningful changes in priority control instrument scores i.e. changes exceeding MCID. However, after qualitatively pooling the evidence the *a priori* thresholdforhypotheses was not fulfilled for either of the measurement properties.

#### ‘Priority’ composite outcome measures for adult severe asthma

The ACCI was awarded sufficient ratings for relevance and comprehensibility, as patients were involved in its development, but comprehensiveness was rated insufficient. Of the other measurement properties appraised, there was only sufficient, albeit ‘low’ quality evidence, for construct validity. ACCI scores had moderate to strong correlations with asthma control and asthma-specific QoL, and relatively weaker correlations with generic QoL.

#### ‘Priority’ quality of life outcome measures for paediatric severe asthma

Content validity was rated inconsistent for all ‘priority’ QoL instruments except the Paediatric Asthma Quality of Life Questionnaire (PAQLQ), which had sufficient evidence for comprehensibility. The quality of evidence was ‘very low’ to ‘low’ as only patients with mild-to-moderate asthma were involved in the development. There was sufficient evidence for other measurement properties appraised, except Mini-PAQLQ, which was rated insufficient for internal consistency. The quality of evidence was predominantly higher for the PAQLQ and Mini-PAQLQ compared to the PAQLQ-S.

#### ‘Priority’ asthma control outcome measures for paediatric severe asthma

The Childhood Asthma Control Test (C-ACT) had the most robust developmental process; there was sufficient ‘moderate’ quality evidence for relevance and comprehensibility, with 28% of the patients in the developmental study diagnosed with severe asthma. The ACT, ACQ-5, ACQ-6, and ACQ-7 received inconsistent and insufficient ratings for relevance and comprehensiveness respectively. However, the ACQ versions performed better than ACT in comprehensibility as children and adolescents were consulted about the phrasing of items and response options. The ‘priority’ asthma control measures were rated sufficient for all measurement properties assessed, except ACT which had insufficient evidence for responsiveness to change. The latter was primarily because the threshold for *a priori* hypotheses as per COSMIN quality criteria was not achieved. In contrast, all ACQ versions had robust responsiveness to change whereby change scores on the instrument had moderate to strong correlations with QoL instrument change scores, and weak correlations with changes in FEV1% predicted. Further, ACQ versions’ and C-ACT mean score changes exceeded the MCID for patients whose asthma was unstable between study visits.

#### ‘Priority’ composite outcome measures for paediatric severe asthma

CASI received inconsistent to insufficient ratings for all components of content validity, primarily because no patients were involved in its development. The internal consistency and test-retest reliability were rated insufficient. As CASI is multidimensional, internal consistency should have been determined for each unidimensional subscale instead of the total score. There was sufficient ‘low’ quality evidence for construct validity, with moderate correlations between CASI and comparators such as symptom days and asthma control. Sufficient ‘moderate’ quality responsiveness to change was shown by an improvement in the treatment group captured by a higher standardized effect size for CASI compared to symptom days.

# DISCUSSION

This systematic review used a multi-step approach to identify and determine the quality of the development and measurement properties of ‘priority’ outcome measures for severe asthma, in accordance with the COSMIN guidelines. The current study is unique as it synthesises evidence for outcome measures which are meaningful to patients with severe asthma, and acceptable to other stakeholders, including healthcare professionals, pharmaceutical, and regulatory representatives. From 96 ‘candidate’ outcome measures identified by the literature search, stakeholders selected 55 ‘key’ outcome measures in a modified Delphi exercise, and subsequently 11 and 13 ‘priority’ outcome measures for adult and paediatric severe asthma respectively. The rationale for excluding outcome measures at each step included lack of relevance for effectiveness studies, poor feasibility in terms of cost and accessibility in pan-European healthcare systems, and redundancy with other outcome measures. Of the ‘priority’ outcome measures, the SAQ and C-ACT had the most robust developmental evidence for the severe asthma population. While other ‘priority’ patient-reported and composite outcome measures had data to support validity and reliability, the quality of evidence was limited primarily by the lack of studies with severe asthma participants. This review has been used as a basis for the development of Core Outcome Measures sets for adult and paediatric Severe Asthma (COMSA)67.

QoL achieved consensus as a ‘priority’ domain, yet it is used as a secondary outcome in most severe asthma studies68. Although QoL only moderately correlates with objective measures69, a higher frequency of exacerbations in patients with moderate-to-severe asthma has been associated with deterioration in QoL70. Additionally, biologics such as mepolizumab show promising improvements in QoL scores71,72. QoL is the most important domain for patients with severe asthma8, outperforming reduction in exacerbation rates. Pertinently, there is an indirect cost patients experience including the burden of daily symptoms resulting in impaired QoL73,74. Future trials should seek to capture this individual disease experience, and ultimately demonstrate QoL benefits beyond the efficacy of a treatment.

Most developmental studies for ‘priority’ QoL measures confounded the construct of QoL with asthma control (symptoms and/or functional status), and were therefore downgraded for comprehensiveness. Similarly, the NIH appraisal highlighted that questionnaires are more likely to assess symptom control instead of QoL impairments experienced due to the ongoing symptoms20. However, the SAQ was developed following the Food and Drug Administration (FDA) guidance14, and thus captures the impact of both asthma symptoms and treatment on QoL specific to adult severe asthma, illustrated by favourable ratings for content validity. A PROM that can capture the QoL limitations as experienced by children and adolescents with severe asthma remains an unmet need.

The majority of PROMs prioritised in this review are legacy measures. They were developed when different approaches to instrument design were accepted, and it was not compulsory to report the detailed methodological steps undertaken. These measures had inconsistent scores on the modern COSMIN appraisal tool. However, legacy PROMs such as the AQLQ continue to be implemented in research and practice68, amplified by their availability in a variety of languages and modes of administration. In contrast, the SAQ has not been utilised widely in research beyond the original studies, probably because it was recently published, so is only now being incorporated into study protocols. Identifying additional barriers impeding the use of modern instruments should enable their uptake by study sponsors across clinical programs.

The prioritisation of asthma control in this review reflects its positionality as an important treatment goal75. An appraisal conducted in 2011 also recommended the asthma control measures selected here as ‘core’ for asthma research16. Although reviews exist about the ‘priority’ control instruments76-78, none assess the methodological quality of measurement properties for severe asthma. The present synthesis highlights the shortcomings of traditional asthma control tools; the quality of evidence is limited for adult instruments due to the lack of patient involvement in their development55,58, while there is a dearth of studies exclusive to the paediatric severe asthma population validating measures designed for patients ≥ 12 years old55,58. However, these asthma control measures are used in the majority of severe asthma trials68, thus investigators should adjust for such limitations when interpreting scores derived from the questionnaires.

Responsiveness to change is a crucial measurement property for any trial endpoint, as poor responsiveness to change can result in false-negative conclusions for the effect of treatment79. Some of the priority outcome measures lacked data which could be assessed using the COSMIN toolkit. Of note, responsiveness to change data for the SAQ were published as a research letter after the search date, and thus not included in the current analysis80,81. If these data were included, the SAQ would have sufficient evidence for responsiveness to change, supporting its status as one of the only measures with robust evidence across the measurement properties assessed. The SAQ is also sensitive to detecting benefits of biologics in severe asthma, supporting its use as a primary endpoint in future clinical trials82. The MCID83 is not considered a measurement property as per COSMIN guidance, but rather an aspect of interpretability, and therefore its quality was not appraised for the ‘priority’ outcome measures. Nonetheless, MCIDs are imperative for endpoints in effectiveness studies, as they represent a clinically relevant change rather than just a statistically significant one.

Despite the lack of validation data for ‘priority’ clinical and HRU endpoints, they are a cornerstone of severe asthma management in practice. In addition, the European Medicine’s Agency (EMA) recommends clinical outcomes such as lung function should be included at least as secondary endpoints in studies investigating treatments for asthma84. Future studies should therefore establish the validity of the ‘priority’ clinical and HRU outcome measures for severe asthma, with a focus on their relevance from a patient-centred standpoint.

Exacerbations are the primary endpoint in most phase III trials investigating new-generation therapies85-88, but the definitions used have immense variability89. A composite tool for severe asthma exacerbations90 developed in patients taking benralizumab was discussed by the multi-stakeholder panel in Step 3 of the review. However, it was not prioritised primarily because it was developed without any input from patients. The panel ratified the ATS/ERS definition of exacerbations2, but a validated tool to capture severe exacerbations acceptable to relevant stakeholders is a significant research gap.

Around 20-60% of adult patients with severe asthma91-93 are prescribed mOCS, and their associated adverse effects2,94 have been shown to impair QoL46. Reduction in OCS use is a treatment priority for these patients8, yet existing adult QoL tools apart from the SAQ fail to capture the unique treatment burden associated with long-term OCS use45. Although mOCS use was also prioritised for paediatric severe asthma, patient representatives voiced that for older adolescents, reduction in OCS use and its associated side effects are a ‘priority’ in some European countries. Healthcare professionals commented that the prioritisation of OCS may differ according to country or healthcare system; mOCS use is not part of the treatment regime for young children in most severe asthma specialist units across Europe. Investigations in paediatric severe asthma cohorts would be valuable in determining the importance of OCS use as a trial endpoint for this population.

Some outcome measures validated in severe asthma, including those utilised for assessing response to biologics, were deprioritised early in the multi-step process. The rationale ranged from lack of patient-centredness and feasibility (poor accessibility in healthcare systems across Europe), to redundancy with other outcome measures. For example, the St George’s Respiratory Questionnaire (SGRQ) has been used in severe asthma trials68. However, stakeholders commented the 50-item instrument was developed primarily for Chronic Obstructive Pulmonary Disease; thus, it may be burdensome for patients to complete, and fail to capture the breadth of experiences unique to patients with severe asthma. Likewise, generic QoL questionnaires are paramount as they enable cross-disease comparisons and calculations of health utility95. But none were prioritised as they are not as sensitive to impairment and change as asthma-specific QoL measures. Researchers and practitioners should adopt this lens of clinical utility and patient-relevance, as opposed to frequency of use, when selecting instruments for clinical trials and patient-monitoring in practice.

## Strengths and limitations

Our study has several strengths. We used a rigorous multi-step process to identify outcome measures considered a ‘priority’ for severe asthma by four stakeholder groups. Higher weighting was placed on patient representatives’ votes to ensure outcome measure selection at each stage of the study was grounded in a patient perspective. The rigorous COSMIN methodology enabled a standardised quality appraisal of included studies with minimal reviewer bias. Although most included studies had participants with a range of asthma severities, the quality of evidence was evaluated in the severe asthma context. This outlook on the evidence will enable readers to select the most appropriate or robust ‘priority’ outcome measure according to their required domain of assessment. Moreover, we engaged adult and paediatric patient and parent/carer representatives to inform the critical appraisal of content validity of outcome measures. The insights provided by patient representatives ranged from conceptual (e.g. importance of fatigue as a QoL deficit experienced by adults with severe asthma), to item design (e.g. preference for a global item to evaluate QoL or asthma control).

We limited our review to studies of English language version of outcome measures published in English, and therefore cross-cultural validity (including measurement invariance) could not be appraised. Other studies have reported the validity of other language versions of ‘priority’ PROMs with a higher percentage of patients with severe asthma than those included in this review, such as QoL96-99 and asthma control99-102 domains. The data reported herein therefore should not be considered exhaustive, but rather an overview of the quality of the available evidence for the severe asthma subgroup. The literature was searched for contemporary ‘candidate’ outcome measures published in a two-year time frame with the safeguard that stakeholders could propose additional outcome measures where justified. The search for studies of ‘priority’ outcome measures was performed in 2020 as the review was undertaken to inform the development of the COMSA67. A worst case scenario was adopted for the overall quality of each study since COSMIN appraisal tools use a ‘worst score counts’ principle, whereby high quality scores may be overridden by the lowest scores returned. Lastly, we undertook a narrative synthesis because the heterogeneity in severe asthma definitions, some of the outcome measures such as exacerbations, and consequently study populations precluded a quantitative (meta-) analysis.

## Implications for research and practice

The findings reported herein informed the COMSA consensus study67. The implementation of the COMSA will create a more consistent and transparent patient-relevant approach across regulatory, value assessment and market access institutions, as well as in clinical trial development. Currently, in most trials the sole selection criterion for selecting endpoints, especially PROMs, is whether they are widely used, with limited regard for the superiority of the quality of measurement properties. This evidence synthesis on the quality of measurement properties should aid researchers and practitioners to choose the most appropriate outcome measures to evaluate treatment response. Further, this review offers insights into the developmental limitations of historically used ‘priority’ QoL and asthma control measures for the severe asthma population. Poor content validity can indirectly hamper the quality of other measurement properties, including responsiveness to change. Regulatory bodies should therefore take caution when interpreting results of trials using legacy endpoints to investigate new-generation therapies for severe asthma. The lack of validation data for clinical and HRU endpoints warrants studies which implement standardised approaches to evaluate their measurement properties in participants with severe asthma.

# CONCLUSION

Outcome measures with robust measurement properties and practical feasibility are a pre-requisite for evidence-based healthcare. This review identified 96 ‘candidate’ outcome measures and used a multi-stakeholder consensus process to select 24 ‘priority’ outcome measures for adult and paediatric severe asthma. Clinical and HRU endpoints are the mainstay as per the regulatory demands for approval of medications, but the validity of these endpoints should be established in adult and paediatric severe asthma as a matter of some urgency. Of the included patient-reported and composite outcome measures, only the SAQ and C-ACT were developed with input from severe asthma patients, supported by predominantly sufficient ‘moderate’ quality evidence for the measurement properties assessed. Further validation in clinical trials, and translation to other languages should enable the SAQ to become a *status quo* QoL endpoint for phase III studies. Despite the ‘low’ to ‘very low’ quality developmental evidence for legacy QoL and asthma control measures, most had sufficient evidence for the measurement properties appraised except responsiveness to change. There is an urgent need to follow contemporary standards14,103,104 when developing new outcome measurement instruments. To that end, researchers should seek to develop a scale for paediatric QoL based on extensive qualitative input from patients with severe asthma and subsequently validate it in studies with good methodological quality.

**Authors’ contributions:**

Study concept and design: GR, AR. Conduct and analysis of modified Delphi exercise, multi-stakeholder meetings, and online voting: AR, EK. Literature searches, data extraction, and COSMIN assessments: AR, EK. Drafting of the original manuscript: AR, EK, GR. All authors provided critical review of the manuscript and approved the final version.

**Funding:**

AR and EK were supported by the European Union Innovative Medicines Initiative 2 (IMI2) 3TR project. GR is funded by University of Southampton and National Institute of Health Research via Southampton’s Biomedical Research Centre. This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 831434 (3TR). The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

**Disclaimer:**

The content of this publication reflects only the authors’ views and the JU is not responsible for any use that may be made of the information it contains.

**Acknowledgements:**

We would like to acknowledge the support of the 3TR (Taxonomy, treatment, targets, and remission) consortium in funding this systematic review. The funder had no role in the development of the protocol, conduct and writing of the review or decision to publish. We would like to thank Paula Sands for her assistance in developing the search strategy and all 3TR Respiratory Work Package members for their contribution. We also acknowledge Thomy Tonia, a methodologist affiliated with ERS, for her constructive feedback on the study protocol. Special thanks to Professor Elizabeth Juniper for her valuable insights regarding outcome measures developed by her group. A part of this manuscript was submitted by AR for her second progression review report for her doctorate degree qualification (University of Southampton, UK).

**Conflict of interest:**

Anna Rattu and Ekaterina Khaleva declare funding from the European Commission’s Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 831434 (3TR) for this manuscript. Chris Brightling declares grants from GSK, AZ, Novartis, Chiesi, BI, Genentech, Roche, Sanofi, Mologic, 4DPharma; consulting fees from GSK, AZ, Novartis, Chiesi, BI, Genentech, Roche, Sanofi, Mologic, 4DPharma, TEVA and support from the 3TR project. Sven-Erik Dahlén declares 3TR IMI Grant; consulting fees for AZ, Cayman Co, GSK, Novartis, Regeneron, Sanofi and Teva; payment for lectures from AZ and Sanofi. Sven-Erik Dahlén declares 3TR IMI Grant; consulting fees for AZ, Cayman Co, GSK, Novartis, Regeneron, Sanofi and Teva; payment for lectures from AZ and Sanofi. Apostolos Bossios declares honoraria for lectures from GSK, AZ, Teva and Novartis; support for attending meetings from AZ and Novartis; honoraria for Advisory Board Meetings from GSK, AZ, Teva, Novartis and Sanofi; being a member of the steering Committee of SHARP, Secretary of Assembly 5 (Airway diseases, asthma, COPD, and chronic cough), European Respiratory Society; Vice-chair of Nordic Severe Asthma Network (NSAN). Louise J Fleming declares participation in advisory boards and honoraria for lectures from Sanofi, Respiri UK, AZ, Novartis and Teva outside of submitted work. All payments were made to her institution. Kian Fan Chung has received honoraria for participating in Advisory Board meetings of GSK, AZ, Roche, Novartis, Merck, and Shionogi regarding treatments for asthma, chronic obstructive pulmonary disease and chronic cough and has also been renumerated for speaking engagements for Novartis & AZ; received MRC grant on Precision Medicine for severe asthma, EPSRC grant on air pollution and asthma and GSK grant on mepolizumab and eosinophils in asthma. Erik Melén declares consulting fees from AZ, Chiesi, Novartis and Sanofi outside the submitted work. Rekha Chaudhuri has received lecture fees from GSK, AZ, Teva, Chiesi, Sanofi and Novartis; honoraria for Advisory Board Meetings from GSK, AZ, Teva, Chiesi, Novartis; sponsorship to attend international scientific meetings from Chiesi, Napp, Sanofi and GSK and a research grant to her Institute from AZ for a UK multi-centre study. Ratko Djukanovic declares funding from ERS, TEVA, GSK, Novartis, Sanofi and Chiesi for the SHARP CRC; consulting fees for Synairgen; honorarium for a lecture from GSK; participation on a Data Safety Monitoring Board or Advisory Board for Kymab (Cambridge) and shares in Synairgen outside of the submitted work. Rekha Chaudhuri has received lecture fees from GSK, AZ, Teva, Chiesi, Sanofi and Novartis; honoraria for Advisory Board Meetings from GSK, AZ, Teva, Chiesi, Novartis; sponsorship to attend international scientific meetings from Chiesi, Napp, Sanofi and GSK and a research grant to her Institute from AZ for a UK multi-centre study. Andrew Exley declares being a minority shareholder in GlaxoSmithKline PLC. Gerard H Koppelman reports receiving research grants from Lung Foundation of the Netherlands, Ubbo Emmius Foundation, H2020 European Union, TEVA the Netherlands, GSK, Vertex, outside this work (money to institution); he reports memberships of advisory boards to GSK and PURE-IMS, outside this work (money to institution). Arnaud Bourdin declares unrestricted grants from AZ and Boeringher Ingelheim to his institute; consulting fees, honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events, and support for attending meetings and travel from AZ, Boeringher Ingelheim, GSK, Novartis, Sanofi; participation on a Data Safety Monitoring Board or Advisory Board for AZ, Boeringher Ingelheim, GSK, Novartis, Sanofi; Abs science. Celeste Porsbjerg declares grants (paid to institution), consulting fees (paid to institution and personal honoraria) and honoraria for lectures (paid to institution and personal honoraria) from AZ, GSK, Novartis, TEVA, Sanofi, Chiesi and ALK; participation in the Advisory Board (paid to institution and personal honoraria) for AZ, Novartis, TEVA, Sanofi and ALK. Courtney Coleman and Clare Williams declare funding received to support this work by European Lung Foundation from European Commission’s Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 831434 (3TR). Elizabeth Davin bought and sold shares on public market during 2021-22 in Regeneron, Roche, and ICON Plc, and declares no current holdings. Phil Taverner declares honorarium for being a lay member of Asthma and Lung UK’s research funding panel, and chairing a Patient and Community Oversight Group for two NIHR health protection research units on environmental and chemical hazards; and payment for chairing a NICE guideline committee on Advocacy Services. Sofia Romagosa Vilarnau declares unrestricted educational grants paid to the organisation from Novartis, Pfizer, Astra Zeneca, Chiesi Farmaceutici, GSK, AbbVie, LeoPharma, Boehringer Ingelheim, Sanofi, Regeneron, OM Pharma, MSD, Roche and DBV Technologies. Graham Roberts declares EU IMI funding and AZ paid to the institution. No other author has any conflict of interest to declare.

# TABLES

**Table 1.** Summary characteristics of priority patient-reported and composite outcome measures.

| Outcome measure  (year) | Target population | Patient/ carer report | Mode(s) of administration | No. of items | Recall period | Response format(s) | Scoring method | Time to complete | Original language, translations\* | License and costs |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Quality of life outcome measures for adults** | | | | | | | | | |
| AQLQ (1993)35 | 17-70 years | Patient | Self-complete, interviewer, paper, online, electronic devices | 32 (4 sub | 2 weeks | 7-point Likert scales. 1 = severely impaired, 7 = not impaired at all. | 4 subscales.  Overall score: mean of responses to all items, range 1-7. | 5-10 minutes | English (North America), 86 translations | Copyrighted by QoL Technologies Ltd.  Paper version: free for non-commercial practice and research. One-time fee for commercial use.  Electronic version: user fee for commercial and academic use. |
| AQLQ-S (1999)42 | 18-70 years | Patient | Self-complete, interviewer, paper, online, electronic devices | 32 | 2 weeks | *Same as AQLQ* | *Same as AQLQ* | 5-15 minutes (4-5 minutes according to Qoltech web site105) | English (North America), 108 translations | *Same as AQLQ* |
| Mini-AQLQ (1999)44 | 18-65 years | Patient | Self-complete, interviewer, paper, electronic devices | 15 | 2 weeks | 7-point Likert scale. 1=all the time, 7=none of the time. | *Same as AQLQ* | 3-4 minutes | English (North America), 83 translations | *Same as AQLQ* |
| SAQ (2018)45 | 16–78 years | Patient | Self-complete, paper | SAQ: 16-items\*  SAQ-global: 1 | 2 weeks | 16-items:  7-point Likert scale. 1=very, very difficult, 7=no problem.  SAQ global:  100-point Borg-type scale.  0=no QoL,  100=perfect QoL. | SAQ score: mean of responses to 16 items, range 1-7.  SAQ-global score: range 0-100. | 3-6 minutes | English (UK), 2 translations | Copyrighted by University of Plymouth and University Hospitals Plymouth NHS Trust.  Free for non-commercial  clinical practice and research.  Fee may apply for funded research, healthcare organizations, commercial users. |
|  | **Quality of life outcome measures for children** | | | | | | | | | |
| PAQLQ (1996)47 | 7-17 years | Patient | Self-complete, interviewer, paper | 23 | 1 week | 7-point Likert scale. 1=severe impairment, 7=no impairment. | 3 subscales. Overall score: mean of responses to all items, range 1-7. | 10-15 minutes at initial visit.  5-10 minutes at follow-up visit. | English (North America), 62 translations | Copyrighted by QoL Technologies Ltd.  Free for use in non-commercial  practice and research. Otherwise, there is a one-time fee. |
| PAQLQ-S (2012)52 | 7-17 years | Patient | Self-complete, interviewer, paper, electronic devices | 23 | 1 week | *Same as PAQLQ* | *Same as PAQLQ* | Not reported | English (North America), 64 translations | *Same as PAQLQ* |
| Mini-PAQLQ (2012)52 | 7 – 17 years | Patient | Self-complete, paper, electronic devices | 13 | 1 week | 7-point Likert scale. 1= maximum impairment, 7= no impairment. | *Same as PAQLQ* | Not reported | English (North America), 18 translations | *Same as PAQLQ* |
|  | **Asthma control outcome measures for children** | | | | | | | | | |
| C-ACT (2007)63 | Children / carer of children aged 4–11 years | Patient and carer | Self-complete, paper, web-based | 7 | 4 weeks | Patient report:  4-point Likert and pictorial scale. 0= ‘very bad’, 3=‘very good’.  Carer report:  6-point Likert scale. 0= ‘everyday’, 5= ‘not at all’. | Total score range: 0-27.  Score ≥19 indicates well-controlled asthma. | 5 minutes (web-based version) | English (USA), 27 translations | Copyrighted by GlaxoSmithKline Ltd.  Free for non-commercial  clinical practice  and research.  Fee may apply for commercial use. |
|  | **Asthma control outcome measures for adults and children** | | | | | | | | | |
| ACQ-7  (adults: 199958, children: 201061) | ≥ 6 years | Patient and clinician | Self-complete (≥11 years), interviewer (6-10 years), paper, interactive web, electronic devices. | 7 (Patient: symptom control, SABA use. Clinician: FEV1% predicted) | 1 week | 7-point Likert scale.  0=no impairment, 6= maximum impairment.  FEV1% predicted scored on 7-point Likert scale. | Total score: mean of responses to all items, range 0-6. | 3 minutes | For adults: English (North America)  For children: English (UK), 111 translations | Copyrighted by QoL Technologies Ltd.  Paper version: free for non-commercial practice and research. One-time fee for commercial use.  Electronic version: user fee for commercial and academic use. |
| ACQ-6  (adult: 200159, children: 201061) | Same as ACQ-7 | Patient | *Same as ACQ-7* | 6 | *Same as ACQ-7* | 7-point Likert scale.  0=no impairment, 6= maximum impairment. | *Same as ACQ-7* | Not reported | *Same as ACQ-7* | *Same as ACQ-7* |
| ACQ-5  (adult: 200159, children: 201061) | Same as ACQ-7 | Patient | *Same as ACQ-7* | 5 | *Same as ACQ-7* | *Same as ACQ-6* | *Same as ACQ-7* | Not reported | *Same as ACQ-7* | *Same as ACQ-7* |
| ACT ¶ (2004)55 | ≥12 years | Patient | Self-complete, interviewer, paper, web-based, telephone, mail. | 5 | 4 weeks | 5-point Likert scale. Items about symptoms and activities:  1=all the time, 5=not at all.  Self-rating of control:  1=not controlled at all, 5=completely controlled. | Total score range: 5-25  Score ≥19 indicates well-controlled asthma. | 1-2 minutes | English (USA),  179 translations106 | Copyrighted by Quality Metric Inc.  Permission required for use. |
|  | **Composite outcome measures for adults** | | | | | | | | | |
| ACCI (2008)65 | ≥12 years | Patient and clinician | Self-complete, paper | Control subscale: 5 | Control subscale:  1 week (2 weeks for night-time awakening item).  Acute care, bother and ‘direction of symptoms’ subscales: ‘since the last clinical visit’. | Multiple choice. Colour coded from green (best), to red (worst). One open-ended question. | Acute care, bother and ‘direction of symptoms’ subscales: Responses converted to numbers; ↑ score = ↓ health status.  Control subscale scored by clinician:  1) 4 categories, ranging from mild intermittent (controlled) to severe-persistent (uncontrolled).  2) Total score assigned to each response, ranging  0-19, ↑score = ↓ control.  3) Yes / no rating of items as 0 (controlled) or 1 (uncontrolled). Summed to provide a problem index, 0-5. ↑ score = ↓ control. | 5-7 minutes | English (USA), Portuguese (Brazil) | Not reported. |
|  | **Composite outcome measures for children** | | | | | | | | | |
| CASI (2012)66 | ≥ 6 years | Patient and clinician | Interviewer, paper, online calculator available | 5 domains: day symptoms and albuterol use, night symptoms and albuterol use, controller medicine, lung function, exacerbations. | 2 weeks: day symptoms and albuterol use, night symptoms and albuterol use, and controller medicine.  2 months: exacerbations | Multiple choice | Responses converted to points with different weights. Total score: sum of points of all items, range 0-20. ↑ score indicates ↑ level of severity. | Not reported | English (USA) | Free to use. |

AQLQ, Asthma Quality of Life Questionnaire; AQLQ-S, Asthma Quality of Life Questionnaire Standardized; Mini-AQLQ, Mini Asthma Quality of Life Questionnaire; SAQ, Severe Asthma Questionnaire; QoL, Quality of Life; PAQLQ, Paediatric Asthma Quality of Life Questionnaire; PAQLQ-S, Paediatric Asthma Quality of Life Questionnaire Standardized; Mini-PAQLQ, Mini Paediatric Asthma Quality of Life Questionnaire; C-ACT, Childhood Asthma Control Test; ACT, Asthma Control Test; ACQ, Asthma Control Questionnaire; ED, Emergency Department; FEV1, forced expiratory volume in 1 second; ACCI, Asthma Control and Communication Instrument; CASI, Composite Asthma Severity Index; QoL, Quality of Life; NA, Non-applicable. **\***: The number of translations is an estimate sourced from sites and manuals of the instruments available in English (not from the systematic literature search). Also, evidence for the validity of the translated versions has not been synthesised as it was outside the scope of the current review.

**Table 2.** Quality of evidence for measurement properties of priority outcome measures for severe asthma.

| Outcome measure | Measurement property | | | | | | | | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Relevance\* | | Comprehensiveness\* | | Comprehensibility\* | | Internal consistency | | Test-retest reliability | | Criterion validity\*\* | | Construct validity | | Responsiveness to change | |
| **Rating** | **GRADE** | **Rating** | **GRADE** | **Rating** | **GRADE** | **Rating** | **GRADE** | **Rating** | **GRADE** | **Rating** | **GRADE** | **Rating** | **GRADE** | **Rating** | **GRADE** |
| *Adult* | | | | | | | | | | | | | | | | |
| *Quality of life* | | | | | | | | | | | | | | | | |
| AQLQ35-41,54 | **±** | ⨁◯◯◯**A,B,C** | **-** | ⨁◯◯◯**A,B,C** | **+** | ⨁⨁◯◯**A,C** | **+** | ⨁⨁⨁◯**C** | **+** | ⨁◯◯◯**A,C** |  |  | **-** | ⨁⨁◯◯**A,C** | **+** | ⨁⨁◯◯**A,C** |
| AQLQ-S41-43¶ | **±** | ⨁⨁◯◯**A,C** | **-** | ⨁⨁◯◯**A,C** | **+** | ⨁◯◯◯**A,B,C** | **+** | ⨁⨁◯◯**B,C** | **+** | ⨁◯◯◯**A,B,C** |  |  | **-** | ⨁⨁◯◯**B,C** | **+#** | ⨁◯◯◯**A,B,C** |
| MiniAQLQ41,44¶ | **±** | ⨁⨁◯◯**A,C** | **-** | ⨁◯◯◯**A,C** | **+** | ⨁⨁◯◯**A,C** | **+** | ⨁⨁◯◯**C,D** | **+** | ⨁⨁◯◯**C,D** | **+** | ⨁◯◯◯**C,D** | **+** | ⨁◯◯◯**A,C,D** | ?**‡** |  |
| SAQ45,46,80,81 | **+** | ⨁⨁⨁◯**A** | **+** | ⨁⨁⨁◯**A** | **+** | ⨁⨁⨁◯**A** | ?**§** |  | **+** | ⨁⨁⨁◯**A** |  |  | **+** | ⨁⨁⨁⨁ | ?**††** |  |
| *Asthma control* | | | | | | | | | | | | | | | | |
| ACT55-57 | **±** | ⨁◯◯◯**A,C** | **-** | ⨁◯◯◯**A,B,C** | **-** | ⨁◯◯◯**A,B,C** | **+** | ⨁⨁⨁◯**C** | **+** | ⨁⨁◯◯**A,C** |  |  | **-** | ⨁⨁◯◯**A,C** | **-** | ⨁◯◯◯**A,C** |
| ACQ558-60 | **±** | ⨁◯◯◯**A,C** | **-** | ⨁◯◯◯**A,C** | **-** | ⨁◯◯◯**A,B,C** | **+** | ⨁⨁⨁◯**C** | **+** | ⨁⨁◯◯**A,C** | **+** | ⨁⨁⨁◯**A,C** | **-** | ⨁◯◯◯**A,C** | **-** | ⨁◯◯◯**A,C** |
| ACQ658-60 | **±** | ⨁◯◯◯**A,C** | **-** | ⨁◯◯◯**A,C** | **-** | ⨁◯◯◯**A,B,C** | **+** | ⨁⨁⨁◯**C** | **+** | ⨁⨁◯◯**A,C** | **+** | ⨁⨁⨁◯**A,C** | **-** | ⨁◯◯◯**A,C** | **-** | ⨁◯◯◯**A,C** |
| *Composite* | | | | | | | | | | | | | | | | |
| ACCI65†† | **+** | ⨁◯◯◯**A,B,C** | **-** | ⨁◯◯◯**A,B,C** | **+** | ⨁◯◯◯**A,B,C** | **-** | ⨁◯◯◯**A,C** | ? |  |  |  | **+** | ⨁⨁◯◯**A,C** | ? |  |
| *Children and adolescents* | | | | | | | | | | | | | | | | |
| *Quality of life* | | | | | | | | | | | | | | | | |
| PAQLQ47-49,51,52 | **±** | ⨁⨁◯◯**A,C** | **±** | ⨁◯◯◯**A,B,C** | **+** | ⨁⨁◯◯**A,C** | **+** | ⨁⨁◯◯ **C,D** | **+** | ⨁⨁⨁◯**C** |  |  | **+** | ⨁⨁⨁◯ **C** | **+** | ⨁⨁◯◯ **A,C** |
| PAQLQ-S47,50-52¶ | **±** | ⨁⨁◯◯**A,C** | **±** | ⨁◯◯◯**A,C** | **±** | ⨁◯◯◯**A,C** | **+** | ⨁◯◯◯**C,D** | **+** | ⨁⨁◯◯ **C,D** |  |  | **+** | ⨁⨁◯◯ **C,D** | **+#** | ⨁◯◯◯ **C,D** |
| MiniPAQLQ51-53¶ | **±** | ⨁◯◯◯**A,B** | **±** | ⨁◯◯◯**A,B** | **±** | ⨁◯◯◯**A,C** | **-** | ⨁⨁⨁◯ **C** | **+** | ⨁⨁◯◯ **C,D** | **+** | ⨁⨁◯◯**C,D** | **+** | ⨁⨁⨁◯ **C** | ?**‡** |  |
| *Asthma control* | | | | | | | | | | | | | | | | |
| ACT55,56 | **±** | ⨁◯◯◯**A,C** | **-** | ⨁◯◯◯**A,B,C** | **-** | ⨁◯◯◯**A,B,C** | **+** | ⨁⨁◯◯**C** | **+** | ⨁◯◯◯ **A,C** |  |  | **+** | ⨁◯◯◯**A,C** | - | ⨁◯◯◯**A,C** |
| CACT63,64 | **+** | ⨁⨁⨁◯**A,C** | **±** | ⨁◯◯◯**A,B,C** | **+** | ⨁⨁⨁◯**A,C** | **+** | ⨁⨁⨁◯ **C** | **+** | ⨁⨁⨁◯**A** |  |  | **+** | ⨁⨁◯◯**A,C** | **+** | ⨁⨁◯◯**A** |
| ACQ558,60,61,107¶† | **±** | ⨁◯◯◯**A,C** | **-** | ⨁◯◯◯**A,C** | **+** | ⨁⨁◯◯**A,C** | **+** | ⨁⨁◯◯**C** | **+** | ⨁◯◯◯**B,C** | **+** | ⨁⨁◯◯**C** | **+** | ⨁◯◯◯**A,C** | **+** | ⨁◯◯◯**A,C** |
| ACQ658,60,61,107¶† | **±** | ⨁◯◯◯**A,C** | **-** | ⨁◯◯◯**A,B,C** | **+** | ⨁⨁◯◯**A,C** | **+** | ⨁⨁◯◯**C** | **+** | ⨁◯◯◯**B,C** | **+** | ⨁⨁◯◯**C** | **+** | ⨁◯◯◯**A,C** | **+** | ⨁◯◯◯**A,C** |
| ACQ758,60-62,107¶† | **±** | ⨁◯◯◯**A,C** | **-** | ⨁◯◯◯**A,B,C** | **+** | ⨁⨁◯◯**A,C** | **+** | ⨁⨁◯◯**C** | **+** | ⨁◯◯◯**B,C** |  |  | **+** | ⨁◯◯◯**A,C** | **+** | ⨁◯◯◯**A,C** |
| *Composite* | | | | | | | | | | | | | | | | |
| CASI66 | **±** | ⨁◯◯◯**A,C** | **-** | ⨁◯◯◯**A,C** | **-** | ⨁◯◯◯**A,C** | **-** | ⨁◯◯◯**A,C** | **-** | ⨁◯◯◯ **A,C** |  |  | **+** | ⨁⨁◯◯**A,C** | **+** | ⨁⨁⨁◯**C** |

AQLQ, Asthma Quality of Life Questionnaire; AQLQ-S, Asthma Quality of Life Questionnaire Standardized; Mini-AQLQ, Mini Asthma Quality of Life Questionnaire; SAQ, Severe Asthma Questionnaire; PAQLQ, Paediatric Asthma Quality of Life Questionnaire; PAQLQ-S, Paediatric Asthma Quality of Life Questionnaire Standardized; Mini-PAQLQ, Mini Paediatric Asthma Quality of Life Questionnaire; ACT, Asthma Control Test; ACQ, Asthma Control Questionnaire; ACQ-5: items about symptom control only; ACQ-6: items about symptom control, and rescue medication use; ACQ-7: items about symptom control, rescue medication use, and forced expiratory volume in 1 second (FEV1) ACCI, Asthma control and communication instrument; GRADE, Grading of Recommendations, Assessment, Development and Evaluation; COSMIN, COnsensus-based Standards for the selection of Measurement Instruments.

Ratings of quality of results for measurement properties was done against COSMIN quality criteria27,32: +, sufficient; ‐, insufficient; ?, indeterminate; ±, inconsistent (for development criteria only). The review team formulated *a priori* hypotheses for appraising construct validity and responsiveness to change; hypotheses included the expected direction and magnitude of correlations between the priority outcome measure and other instruments, and expected mean differences in scores between groups. A sufficient rating was awarded if ≥75% of the hypotheses were fulfilled for pooled results of the measurement property. Ratings are based on data from the studies published in English for the English language version of the instrument only. See online supplement for detailed results.

Certainty of evidence was evaluated using the modified GRADE approach27,34. For content validity, this considers: A. risk of bias, B. inconsistency, C. indirectness, and for grading other measurement properties, an additional factor of D. imprecision.

\*: Results are a combination of data from the publication (views of patients and/or professionals), and ratings by review team.

\*\*: Criterion validity was not assessed for the full-versions of patient-reported and composite instruments as there is no gold standard.

¶: There is moderate and high concordance between this shortened/standardised version and the original instrument.

††: Responsiveness data were published after the search was run. See discussion for further details.

§: Internal consistency was only evaluated for the total scale score of the SAQ assessed to be multi-dimensional by the review team, and thus not eligible for assessment as per COSMIN methodology. A study published after the search was run established subscales for the SAQ and reported their internal consistency80.

#: Responsiveness assessed for overall score, symptoms, and emotional functioning subscales using minimal important difference (MID) established for original questionnaire. The responsiveness of the activity subscale could not be calculated using the MID established for the original questionnaire as it has been modified (patient-specific activities replaced with standardised activities).

‡: Responsiveness could not be assessed as a Minimal Clinical Important Difference (MCID), or MID has not been established for this outcome measure.

†: Development of ACQ versions for the paediatric population was presented at a conference.

††: The ACCI developmental process was presented at a conference108,109.

# REFERENCE LIST

1. To T, Stanojevic S, Moores G, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. *BMC Public Health* 2012;12:204.

2. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. *Eur Respir J* 2014;43(2):343-73.

3. World Health Organization. *Asthma*. <https://www.who.int/news-room/facts-in-pictures/detail/asthma> (accessed 2022 April 15).

4. Backman H, Jansson SA, Stridsman C, et al. Severe asthma-A population study perspective. *Clin Exp Allergy* 2019;49(6):819-28.

5. Braman SS. The global burden of asthma. *Chest* 2006;130(1 Suppl):4s-12s.

6. Hyland ME, Whalley B, Jones RC, et al. A qualitative study of the impact of severe asthma and its treatment showing that treatment burden is neglected in existing asthma assessment scales. *Qual Life Res* 2015;24(3):631-9.

7. O'Neill S, Sweeney J, Patterson CC, et al. The cost of treating severe refractory asthma in the UK: an economic analysis from the British Thoracic Society Difficult Asthma Registry. *Thorax* 2015;70(4):376-8.

8. Clark VL, Gibson PG, McDonald VM. What matters to people with severe asthma? Exploring add-on asthma medication and outcomes of importance. *ERJ Open Res* 2021;7(1).

9. Stubbs MA, Clark VL, McDonald VM. Living well with severe asthma. *Breathe (Sheff)* 2019;15(2):e40-e49.

10. McDonald VM, Kennington EJ, Hyland ME. Understanding the experience of people living with severe asthma. *Eur Respir Monogr* 2019;89:16-29.

11. Normansell R, Walker S, Milan SJ, et al. Omalizumab for asthma in adults and children. *Cochrane Database Syst Rev* 2014(1):Cd003559.

12. Nair P, Wenzel S, Rabe KF, et al. Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. *N Engl J Med* 2017;376(25):2448-58.

13. Rabe KF, Nair P, Brusselle G, et al. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. *N Engl J Med* 2018;378(26):2475-85.

14. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), et al. *Guidance for industry: patient-reported outcome measures: use in medicinal product development to support labelling claims.* <https://www.fda.gov/media/77832/download> (accessed 2022 April 15).

15. Akinbami LJ, Sullivan SD, Campbell JD, et al. Asthma outcomes: healthcare utilization and costs. *The Journal of allergy and clinical immunology* 2012;129(3 Suppl):S49-64.

16. Cloutier MM, Schatz M, Castro M, et al. Asthma outcomes: composite scores of asthma control. *The Journal of allergy and clinical immunology* 2012;129 3 Suppl:S24-33.

17. Krishnan JA, Lemanske RFJ, Canino GJ, et al. Asthma outcomes: symptoms. *J Allergy Clin Immunol* 2012;129(3 Suppl):S124-35.

18. Szefler SJ, Wenzel S, Brown R, et al. Asthma outcomes: biomarkers. *J Allergy Clin Immunol* 2012;129(3 Suppl):S9-23.

19. Tepper RS, Wise RS, Covar R, et al. Asthma outcomes: pulmonary physiology. *J Allergy Clin Immunol* 2012;129(3 Suppl):S65-87.

20. Wilson SR, Rand CS, Cabana MD, et al. Asthma outcomes: quality of life. *The Journal of allergy and clinical immunology* 2012;129(3 Suppl):S88-S123.

21. Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. *Eur Respir J* 2020;55(1).

22. Clark VL, Gibson PG, McDonald VM. The Patients' Experience of Severe Asthma Add-On Pharmacotherapies: A Qualitative Descriptive Study. *J Asthma Allergy* 2021;14:245-58.

23. Upham JW, Le Lievre C, Jackson DJ, et al. Defining a Severe Asthma Super-Responder: Findings from a Delphi Process. *J Allergy Clin Immunol Pract* 2021;9(11):3997-4004.

24. McQueen RB, Sheehan DN, Whittington MD, et al. Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations. *Pharmacoeconomics* 2018;36(8):957-71.

25. Foster JM, McDonald VM, Guo M, et al. "I have lost in every facet of my life": the hidden burden of severe asthma. *Eur Respir J* 2017;50(3).

26. Mokkink LB, de Vet HCW, Prinsen CAC, et al. COSMIN Risk of Bias checklist for systematic reviews of Patient-Reported Outcome Measures. *Qual Life Res* 2018;27(5):1171-79.

27. Prinsen CAC, Mokkink LB, Bouter LM, et al. COSMIN guideline for systematic reviews of patient-reported outcome measures. *Qual Life Res* 2018;27(5):1147-57.

28. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009;6(7):e1000097.

29. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. *J Clin Epidemiol* 2011;64(4):395-400.

30. Khaleva E, Rattu A, Brightling C, et al. Development of Core Outcome Measures sets for paediatric and adult Severe Asthma (COMSA) [Preprint]. *Eur Respir J* 2022.

31. Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan-a web and mobile app for systematic reviews. *Syst Rev* 2016;5(1):210.

32. Terwee CB, Prinsen CAC, Chiarotto A, et al. COSMIN methodology for evaluating the content validity of patient-reported outcome measures: a Delphi study. *Qual Life Res* 2018;27(5):1159-70.

33. Mokkink LB, Boers M, van der Vleuten CPM, et al. COSMIN Risk of Bias tool to assess the quality of studies on reliability or measurement error of outcome measurement instruments: a Delphi study. *BMC Med Res Methodol* 2020;20(1):293.

34. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. *J Clin Epidemiol* 2011;64(4):383-94.

35. Juniper EF, Guyatt GH, Ferrie PJ, et al. Measuring Quality-of-Life in Asthma. *American Review of Respiratory Disease* 1993;147(4):832-38.

36. Aburuz S, Gamble J, Heaney LG. Assessment of impairment in health-related quality of life in patients with difficult asthma: psychometric performance of the Asthma Quality of Life Questionnaire. *Respirology* 2007;12(2):227-33.

37. Leidy NK, Coughlin C. Psychometric performance of the Asthma Quality of Life Questionnaire in a US sample. *Quality of Life Research* 1998;7(2):127-34.

38. Leidy NK, Chan KS, Coughlin C. Is the asthma quality of life questionnaire a useful measure for low- income asthmatics? *American Journal of Respiratory and Critical Care Medicine* 1998;158(4):1082-90.

39. Chhabra SK, Kaushik S. Validation of the asthma quality of life questionnaire (AQLQ-UK English version) in Indian asthmatic subjects. *Indian Journal of Chest Diseases & Allied Sciences* 2005;47(3):167-73.

40. Wyrwich KW, Tierney WM, Wolinsky FD. Using the standard error of measurement to identify important changes on the Asthma Quality of Life Questionnaire. *Quality of Life Research* 2002;11(1):1-7.

41. Juniper EF, Guyatt GH, Epstein RS, et al. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. *Thorax* 1992;47(2):76-83.

42. Juniper EF, Buist AS, Cox FM, et al. Validation of a standardized version of the Asthma Quality of Life Questionnaire. *Chest* 1999;115(5):1265-70.

43. Tan WC, Tan JWL, Wee EWL, et al. Validation of the English version of the Asthma Quality of Life Questionnaire in a multi-ethnic Asian population. *Quality of Life Research* 2004;13(2):551-56.

44. Juniper EF, Guyatt GH, Cox FM, et al. Development and validation of the Mini Asthma Quality of Life Questionnaire. *European Respiratory Journal* 1999;14(1):32-8.

45. Hyland ME, Jones RC, Lanario JW, et al. The construction and validation of the Severe Asthma Questionnaire. *European Respiratory Journal* 2018;52(1):1800618.

46. Hyland ME, Lanario JW, Pooler J, et al. How patient participation was used to develop a questionnaire that is fit for purpose for assessing quality of life in severe asthma. *Health and Quality of Life Outcomes* 2018;16(1):24.

47. Juniper EF, Guyatt GH, Feeny DH, et al. Measuring quality of life in children with asthma. *Quality of Life Research* 1996;5(1):35-46.

48. Juniper EF, Guyatt GH, Feeny DH, et al. Minimum skills required by children to complete health-related quality of life instruments for asthma: comparison of measurement properties. *European Respiratory Journal* 1997;10(10):2285-94.

49. Elizabeth C, Suzanna S, Tim CF, et al. Pediatric Asthma Quality of Life Questionnaire: Validation in children from Singapore. *Asian Pacific Journal of Allergy and Immunology* 1999;17(3):155-61.

50. Bushnell DM, Martin ML, Parasuraman B. Electronic versus paper questionnaires: a further comparison in persons with asthma. *Journal of Asthma* 2003;40(7):751-62.

51. Townsend M, Feeny DH, Guyatt GH, et al. Evaluation of the burden of illness for pediatric asthmatic patients and their parents. *Ann Allergy* 1991;67(4):403-8.

52. Wing A, Upton J, Svensson K, et al. The standardized and mini versions of the PAQLQ are valid, reliable, and responsive measurement tools. *Journal of Clinical Epidemiology* 2012;65(6):643-50.

53. Mahabaleshwarkar R, Taylor YJ, Tapp H, et al. Psychometric Properties of the Mini Pediatric Asthma Quality of Life Questionnaire in a US Sample. *Pediatric Allergy, Immunology, and Pulmonology* 2016;29(3):137-42.

54. Apfelbacher CJ, Jones CJ, Frew A, et al. Validity of three asthma-specific quality of life questionnaires: the patients' perspective. *BMJ Open* 2016;6(12):e011793.

55. Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test: A survey for assessing asthma control. *Journal of Allergy and Clinical Immunology* 2004;113(1):59-65.

56. Schatz M, Sorkness CA, Li JT, et al. Asthma Control Test: Reliability, validity, and responsiveness in patients not previously followed by asthma specialists. *Journal of Allergy and Clinical Immunology* 2006;117(3):549-56.

57. Schatz M, Kosinski M, Yarlas AS, et al. The minimally important difference of the Asthma Control Test. *Journal of Allergy and Clinical Immunology* 2009;124(4):719-23.

58. Juniper EF, O'Byrne PM, Guyatt GH, et al. Development and validation of a questionnaire to measure asthma control. *European Respiratory Journal* 1999;14(4):902-7.

59. Juniper EF, O'Byrne PM, Roberts JN. Measuring asthma control in group studies: do we need airway calibre and rescue beta2-agonist use? *Respir Med* 2001;95(5):319-23.

60. Wyrwich KW, Khan SA, Navaratnam P, et al. Validation and agreement across four versions of the asthma control questionnaire in patients with persistent asthma. *Respiratory Medicine* 2011;105(5):698-712.

61. Juniper EF, Gruffydd-Jones K, Ward S, et al. Asthma Control Questionnaire in children: validation, measurement properties, interpretation. *European Respiratory Journal* 2010;36(6):1410-16.

62. Nguyen JM, Holbrook JT, Wei CY, et al. Validation and psychometric properties of the Asthma Control Questionnaire among children. *Journal of Allergy and Clinical Immunology* 2014;133(1):91-97.e6.

63. Liu AH, Zeiger R, Sorkness C, et al. Development and cross-sectional validation of the Childhood Asthma Control Test. *Journal of Allergy and Clinical Immunology* 2007;119(4):817-25.

64. Bime C, Gerald JK, Wei CY, et al. Measurement characteristics of the childhood Asthma-Control Test and a shortened, child-only version. *NPJ Primary Care Respiratory Medicine* 2016;26:16075.

65. Patino CM, Okelo SO, Rand CS, et al. The Asthma Control and Communication Instrument: A clinical tool developed for ethnically diverse populations. *Journal of Allergy and Clinical Immunology* 2008;122(5):936-43.

66. Wildfire JJ, Gergen PJ, Sorkness CA, et al. Development and validation of the Composite Asthma Severity Index-an outcome measure for use in children and adolescents. *Journal of Allergy and Clinical Immunology* 2012;129(3):694-701.

67. Khaleva E, Rattu A, Brightling C, et al. Development of Core Outcome Measures sets for Adult and Paediatric Severe Asthma (COMSA). European Respiratory Journal, In Press, 2022.

68. Lanario JW, Burns L. Use of Health Related Quality of Life in Clinical Trials for Severe Asthma: A Systematic Review. *J Asthma Allergy* 2021;14:999-1010.

69. Moy ML, Israel E, Weiss ST, et al. Clinical predictors of health-related quality of life depend on asthma severity. *Am J Respir Crit Care Med* 2001;163(4):924-9.

70. Luskin AT, Chipps BE, Rasouliyan L, et al. Impact of asthma exacerbations and asthma triggers on asthma-related quality of life in patients with severe or difficult-to-treat asthma. *J Allergy Clin Immunol Pract* 2014;2(5):544-52.e1-2.

71. Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. *Lancet Respir Med* 2017;5(5):390-400.

72. Emma R, Morjaria JB, Fuochi V, et al. Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience. *Ther Adv Respir Dis* 2018;12:1753466618808490.

73. Van Ganse E, Laforest L, Pietri G, et al. Persistent asthma: disease control, resource utilisation and direct costs. *Eur Respir J* 2002;20(2):260-7.

74. Balter M, Ernst P, Watson W, et al. Asthma worsenings: approaches to prevention and management from the Asthma Worsenings Working Group. *Can Respir J* 2008;15 Suppl B(Suppl B):1b-19b.

75. Global Initiative for Asthma (GINA). *Global Strategy for Asthma Management and Prevention.* <http://ginasthma.org/>.

76. Voorend-van Bergen S, Vaessen-Verberne AA, de Jongste JC, et al. Asthma control questionnaires in the management of asthma in children: A review. *Pediatr Pulmonol* 2015;50(2):202-8.

77. Dinakar C, Chipps BE. Clinical Tools to Assess Asthma Control in Children. *Pediatrics* 2017;139(1).

78. Alzahrani YA, Becker EA. Asthma Control Assessment Tools. *Respir Care* 2016;61(1):106-16.

79. Higgins J, Thomas J, Chandler J, et al. *Cochrane Handbook for Systematic Reviews of Interventions version 6.2* Cochrane 2022. <www.training.cochrane.org/handbook> (accessed 2022 15 April).

80. Lanario JW, Hyland ME, Menzies-Gow A, et al. Validation of subscales of the Severe Asthma Questionnaire (SAQ) using exploratory factor analysis (EFA). *Health Qual Life Outcomes* 2020;18(1):336.

81. Masoli M, Lanario JW, Hyland ME, et al. The Severe Asthma Questionnaire: sensitivity to change and minimal clinically important difference (MCID). *Eur Respir J* 2021;57(6):2100300.

82. Hyland ME, Lanario JW, Menzies-Gow A, et al. Comparison of the sensitivity of patient-reported outcomes for detecting the benefit of biologics in severe asthma. *Chron Respir Dis* 2021;18:14799731211043530.

83. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. *Control Clin Trials* 1989;10(4):407-15.

84. European Medicines Agency. *Guideline on the clinical investigation of medicinal products for the treatment of asthma*. <https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-asthma_en.pdf> (accessed 2022 April 15).

85. Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. *Lancet Respir Med* 2015;3(5):355-66.

86. FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet* 2016;388(10056):2128-41.

87. Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. *N Engl J Med* 2013;368(26):2455-66.

88. Moore WC, Kornmann O, Humbert M, et al. Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). *Eur Respir J* 2022;59(1).

89. Tejwani V, Chang HY, Tran AP, et al. The asthma evidence base: a call for core outcomes in interventional trials. *J Asthma* 2021;58(7):855-64.

90. Fuhlbrigge AL, Bengtsson T, Peterson S, et al. A novel endpoint for exacerbations in asthma to accelerate clinical development: a post-hoc analysis of randomised controlled trials. *Lancet Respir Med* 2017;5(7):577-90.

91. Bleecker ER, Menzies-Gow AN, Price DB, et al. Systematic Literature Review of Systemic Corticosteroid Use for Asthma Management. *Am J Respir Crit Care Med* 2020;201(3):276-93.

92. Voorham J, Xu X, Price DB, et al. Healthcare resource utilization and costs associated with incremental systemic corticosteroid exposure in asthma. *Allergy* 2019;74(2):273-83.

93. Wang E, Wechsler ME, Tran TN, et al. Characterization of Severe Asthma Worldwide: Data From the International Severe Asthma Registry. *Chest* 2020;157(4):790-804.

94. Chung LP, Upham JW, Bardin PG, et al. Rational oral corticosteroid use in adult severe asthma: A narrative review. *Respirology* 2020;25(2):161-72.

95. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. *Ann Intern Med* 1993;118(8):622-9.

96. Abdel Hai R, Taher E, Abdel Fattah M. Assessing validity of the adapted Arabic Paediatric Asthma Quality of Life Questionnaire among Egyptian children with asthma. *Eastern Mediterranean Health Journal* 2010;16(3):274-80.

97. Tauler E, Vilagut G, Grau G, et al. The Spanish version of the Paediatric Asthma Quality of Life Questionnaire (PAQLQ): Metric characteristics and equivalence with the original version. *Quality of Life Research* 2001;10(1):81-91.

98. Mussaffi H, Omer R, Prais D, et al. Computerised paediatric asthma quality of life questionnaires in routine care. *Archives of Disease in Childhood* 2007;92(8):678-82.

99. Ehrs PO, Nokela M, Ställberg B, et al. Brief questionnaires for patient-reported outcomes in asthma: validation and usefulness in a primary care setting. *Chest* 2006;129(4):925-32.

100. Schuler M, Faller H, Wittmann M, et al. Asthma Control Test and Asthma Control Questionnaire: factorial validity, reliability and correspondence in assessing status and change in asthma control. *Journal of Asthma* 2016;53(4):438-45.

101. Sekerel BE, Soyer OU, Keskin O, et al. The reliability and validity of Turkish version of Childhood Asthma Control Test. *Quality of Life Research* 2012;21(4):685-90.

102. Picado C, Badiola C, Perulero N, et al. Validation of the Spanish version of the Asthma Control Questionnaire. *Clinical Therapeutics* 2008;30(10):1918-31.

103. Carlton J, Peasgood T, Khan S, et al. An emerging framework for fully incorporating public involvement (PI) into patient-reported outcome measures (PROMs). *J Patient Rep Outcomes* 2020;4(1):4.

104. Wild D, Grove A, Martin M, et al. Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. *Value Health* 2005;8(2):94-104.

105. Juniper EF. *Standardised Asthma Quality of Life Questionnaire (AQLQ(S))*. <http://www.qoltech.co.uk/aqlq_s.html> (accessed 2022 April 15).

106. QualityMetric Asthma Control Test™ (ACT™). *A 5-item PRO survey designed to measure the impairment domain of asthma control as defined by the National Heart, Lung, and Blood Institute (NHLBI).* <https://www.qualitymetric.com/health-surveys/asthma-control-test-act/> (accessed 2022 April 15).

107. Juniper EF, Gruffydd-Jones K, Ward S, et al. Developing an interviewer-administered version of the asthma control questionnaire (ACQ) for children ≤10 years. *Eur Respir J* 2007;30(Suppl. 51):2274.

108. Patino CM, Riekert KA, Quartey RI, et al. Development of the Asthma and Control and Communication Instrument (ACCI). *Am J Respir Crit Care Med* 2005;2:A254.

109. Patino CM, Quartey RI, Rand CS, et al. Physician rationale in assigning asthma treatment: is it based on guidelines? *Am J Respir Crit Care Med* 2004;169:A365.